Acadia Pharmaceuticals Inc 10-Q for FY2026 Q3
Acadia Pharmaceuticals Inc (ACAD)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 06, 2026
About this 10-Q
Acadia Pharmaceuticals Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Acadia Pharmaceuticals reported nine-month net product sales of $918.3 million versus $787.5 million, with DAYBUE products at $366.1 million and NUPLAZID at $552.2 million. It continues two Phase 3 studies using a once daily 60 mg dose. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $342.29M
- up 22.8% from $278.63M a year earlier
- Net income
- $53.52M
- down 25.4% from net income of $71.78M a year earlier
- Diluted EPS
- $0.31
- down 26.2% from $0.42 a year earlier